Abstract
Macroeconomic variables primarily related to the health care system are the result of two key factors. On the one hand, the results obtained for preserving the health of individuals improving, also, the quality of life and, on the other hand, the costs to be supported in order to reach these results. There is evidence that a balance between these two parameters must be obtained in an era of limited economic resources and, therefore, measures, which can achieve these variables, are under study.
Cost-effectiveness ratio is the most economic factor analyzed still lending to define the relationship between costs and disease. With regard to cardiovascular risk, budgets not always in line with established expectations are under exam.
Quantitative measures related to cost-effectiveness ratio as the estimate-score system, which sets specific scores for the symptoms of the disease, are studied to improve the budget that regulates costs and results on public health including cardiovascular risk characterized by a high frequency of adverse events.
Keywords: Economic costs, cost-effectiveness ratio, cardiovascular risk, health care system, budgets, parameters, estimate-score system, economic resources, balance, parameters
Current Pharmaceutical Design
Title:The Economic Costs for the Control of Cardiovascular Risk: An Overview
Volume: 19 Issue: 13
Author(s): Aldo Leone
Affiliation:
Keywords: Economic costs, cost-effectiveness ratio, cardiovascular risk, health care system, budgets, parameters, estimate-score system, economic resources, balance, parameters
Abstract: Macroeconomic variables primarily related to the health care system are the result of two key factors. On the one hand, the results obtained for preserving the health of individuals improving, also, the quality of life and, on the other hand, the costs to be supported in order to reach these results. There is evidence that a balance between these two parameters must be obtained in an era of limited economic resources and, therefore, measures, which can achieve these variables, are under study.
Cost-effectiveness ratio is the most economic factor analyzed still lending to define the relationship between costs and disease. With regard to cardiovascular risk, budgets not always in line with established expectations are under exam.
Quantitative measures related to cost-effectiveness ratio as the estimate-score system, which sets specific scores for the symptoms of the disease, are studied to improve the budget that regulates costs and results on public health including cardiovascular risk characterized by a high frequency of adverse events.
Export Options
About this article
Cite this article as:
Leone Aldo, The Economic Costs for the Control of Cardiovascular Risk: An Overview, Current Pharmaceutical Design 2013; 19 (13) . https://dx.doi.org/10.2174/1381612811319130013
DOI https://dx.doi.org/10.2174/1381612811319130013 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Psychological Stress and the Development of Heart Disease
Current Psychiatry Reviews Structure, Production and Function of Erythropoietin: Implications for Therapeutical Use in Cardiovascular Disease
Current Medicinal Chemistry Selenium Deficiency in Soils and Crops and its Impact on Animal and Human Health
Current Nutrition & Food Science Wound-Associated Skin Fibrosis: Mechanisms and Treatments Based on Modulating the Inflammatory Response
Endocrine, Metabolic & Immune Disorders - Drug Targets A Multicenter Prospective Hospital-based Cohort Study on the Efficacy and Safety of Pitavastatin
Current Diabetes Reviews The Prothrombotic State in Hypertension and the Effects of Antihypertensive Treatment
Current Pharmaceutical Design Metronidazole Loaded Polycaprolactone-Carbopol Blends Based Biodegradable Intrapocket Dental Film for Local Treatment of Periodontitis
Drug Delivery Letters Osteoporosis Entwined with Cardiovascular Disease: The Implication of Osteoprotegerin and the Example of Statins
Current Medicinal Chemistry Is High Oral Dose L-arginine Intake Effective in Leukoaraiosis? Preliminary Data, Study Protocol and Expert’s Opinion
Current Aging Science Drug Treatment of Metabolic Syndrome
Current Clinical Pharmacology Analysis of Parallel SVM Based Classification Technique on Healthcare using Big Data Management in Cloud Storage
Recent Patents on Computer Science Peripheral Arterial Disease in Persons with Diabetic Foot Ulceration: a Current Comprehensive Overview
Current Diabetes Reviews From fungus to pharmaceuticals – the chemistry of statins
Mini-Reviews in Medicinal Chemistry The Heart Metabolism: Pathophysiological Aspects in Ischaemia and Heart Failure
Current Pharmaceutical Design Genistein as a Potential Anticancer Agent Against Head and Neck Squamous Cell Carcinoma
Current Topics in Medicinal Chemistry Generation of Human Cardiomyocytes for Cardiac Regenerative Therapies: Differentiation and Direct Reprogramming
Current Pharmaceutical Design Electroporation Gene Therapy: New Developments In Vivo and In Vitro
Current Gene Therapy Combined QSAR Model and Chemical Similarity Search for Novel HMG-CoA Reductase Inhibitors for Coronary Heart Disease
Current Computer-Aided Drug Design Cardiac Arrhythmias in Patients with Chronic Kidney Disease: Implications of Renal Failure for Antiarrhythmic Drug Therapy
Current Medicinal Chemistry Extraction, Processing, and Stabilization of Health-Promoting Fish Oils
Recent Patents on Food, Nutrition & Agriculture